Antihypertensive Drug Treatment and the Risk for Intrahemodialysis Hypotension
- 16 July 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (10) , 1310-1318
Abstract
Key Points: Antihypertensive medications are often used by hemodialysis patients, and intradialytic hypotension is a common complication in these patients. The study emulates a randomized clinical trial comparing antihypertensive drug treatment for the risk of hemodialysis hypotension in 4072 incident patients. Compared with calcium antagonists, β and α–β blockers, angiotensin converting enzyme inhibitors or angiotensin II antagonists, and diuretics may increase the risk of hemodialysis hypotension. Background: Antihypertensive medications are often prescribed to manage hypertension in hemodialysis patients, and intradialytic hypotension (IDH) is a common complication in these patients. We investigated the risk of IDH in incident hemodialysis patients who initiated treatment with antihypertensive drugs in monotherapy. Methods: The study was conducted as an emulation of a randomized clinical trial in 4072 incident hemodialysis patients who started antihypertensive drug treatment between January 2016 and December 2019. The primary outcome was the occurrence of IDH during hemodialysis sessions. The generalized estimating equation analysis was adjusted by inverse probability treatment weighting. Results: Calcium channel blocker (CCB) use was associated with an IDH incidence rate of 7.4 events per person-year (95% confidence interval [CI], 6.2 to 8.6). Compared with CCB use, use of β and α–β blockers was strongly associated with a higher likelihood of IDH (odds ratio [OR] [95% CI, 2.27; 1.50 to 3.43]). The use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (OR [95% CI, 1.71; 1.14 to 2.57]) and diuretics (OR [95% CI, 1.52; 1.07 to 2.16]) were also associated with a higher likelihood of IDH compared with CCB use. Conclusions: The study suggests that using β and α–β blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and diuretics may increase the risk of IDH in hemodialysis patients compared with CCB use.Keywords
This publication has 40 references indexed in Scilit:
- From electronic health records to clinical management systems: how the digital transformation can support healthcare servicesClinical Kidney Journal, 2023
- Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome themClinical Kidney Journal, 2020
- Intradialytic Hypertension Frequency and Short-Term Clinical Outcomes Among Individuals Receiving Maintenance HemodialysisAmerican Journal of Hypertension, 2017
- Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analysesJournal of Clinical Epidemiology, 2016
- The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled TrialAmerican Journal of Kidney Diseases, 2016
- Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of StatinsAmerican Journal of Epidemiology, 2012
- Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotensionKidney International, 2008
- Diuretic Use, Residual Renal Function, and Mortality Among Hemodialysis Patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS)American Journal of Kidney Diseases, 2007
- Baroreflex Function in Hypertension: Consequences for Antihypertensive TherapyProgress in Cardiovascular Diseases, 2006
- Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patientsAmerican Journal of Kidney Diseases, 2003